Cell cycle modulation enhances the cytotoxicity of thymidylate synthase inhibitors by Sigmond, J. et al.
Pteridines / Vol. 20 / Special issue
128 J. Sigmond et al. : Cell cycle modulation and thymidylate synthase
Pteridines
Vol. 20, Special issue, pp. 128-136
Cell Cycle Modulation Enhances the Cytotoxicity of 
Thymidylate Synthase Inhibitors
Jennifer Sigmond, Bistra Todorova, Kees Smid, Godefridus J Peters§ 
Department of Medical Oncology, VU University Medical Center PO Box 7057, 
1007 MB Amsterdam, the Netherlands
Abstract 
Thymidylate synthase (TS) is a cell cycle regulated enzyme. It increases during proliferation and 
has a higher activity during the S-phase in order to provide the cell with sufficient dTTP to facilitate 
DNA synthesis. Hence inhibition of cyclin dependent kinases (CdK) may lead to a decrease of TS 
and enhance the inhibition of TS. A number of CdKs control progress of the cell cycle together with 
checkpoint kinases (ChK1 and ChK2) which are activated by phosphorylation mediated by protein 
kinases such as protein kinase C (PKC). Both staurosporine (STS) and UCN-01 are inhibitors of PKC, 
but STS also inhibits CdK2, while UCN-01 inhibits CdK2, 4 and 6 as well as ChK1, cyclin D and 
pRb. We investigated the interaction between 5-fluorouracil (5FU) and STS or UCN-01 in syngeneic 
colon cancer cells, either wild type for p53 (LovoB2) or mutated (Lovo175x2). Cell growth inhibition 
was evaluated using the sulforhodamine B (SRB) test, synergism was evaluated using the multiple 
drug effect analysis yielding combination indices (CI: synergism < 0.9; antagonism: > 1.1), cell cycle 
distribution and cell death by FACS analysis, cell cycle proteins by western blots, while TS expression 
was measured by radioactive assays. 5FU was combined with STS or UCN-01 using simultaneous and 
sequential schedules. Cytotoxicity of 5FU was enhanced by UCN-01 (LovoB2, CI=0.4; Lovo175x2, 
CI=0.2) but less for STS (CI=0.8-0.9). At IC80 values, 5FU (5 µM) induced an S-phase arrest (2-3 
fold) in both cell lines, 0.5 µM UCN-01 a slight decrease in G2-M arrest but 0.05 µM STS not. 5FU 
and UCN-01 combinations all decreased G2-M phase. STS and 5FU combinations led to a similar 
S-phase accumulation as with 5FU. Induction of cell kill after 48 hr by UCN-01 was independent of 
p53, as it was 2-3 fold higher (25%) in Lovo175x2 cells compared to LovoB2, for STS this was similar 
for both cell lines (5-10%), as well as for 5FU (2-5%). Combinations of 5FU and STS or UCN-01 
resulted in additive cell kill in both cell lines. At a molecular level 5FU caused an increase in TS levels 
(predominantly as the ternary complex), STS downregulated TS partially, but UCN-01 completely, 
which was associated with a similar decrease in E2F. STS, UCN-01 and 5FU treatment also decreased 
TS catalytic activity in both cell lines. 5FU caused a transient appearance of pChK expression at 24 
hr which was enhanced by UCN-01 and STS. In conclusion: the effect of 5FU can be enhanced by the 
cell cycle modulators UCN-01 and STS, by abrogation of either the S or G2M checkpoints.
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Introduction
Thymidylate synthase (TS) is a rate-limiting 
enzyme in pyrimidine de novo deoxynucleotide 
biosynthesis. TS catalyzes the methylation of 2’-
deoxyuridine-5’-monophosphate (dUMP) to 2’-
deoxythymidine-5’- monophosphate (dTMP), 
with 5,10-methylene tetrahydrofolate (5-10-
CH2-THF) as a limiting cofactor (1). dTMP 
can be converted into 2’-deoxythymidine-5’- 
triphosphate (dTTP), an essential precursor 
for DNA synthesis. Expression of TS under 
physiological conditions is related to the cell 
cycle and has a high activity during the S-phase, 
but decreases when the cells do not proliferate 
(1). Various transcription factors and cell cycle-
dependent kinases (CDK) control the increase 
in TS levels in the cell cycle (2). Cell cycle 
progress through the G1/S checkpoint is tightly 
regulated by cyclin/CDK complexes, which are 
activated by phosphorylation. Phosphorylation 
of various cyclins-CDKs can subsequently 
hyperphosphosphorylate the Rb and E2F 
complex which results in the release of E2F from 
phosphorylated Rb. The free transcription factor 
E2F can subsequently activate the transcription of 
several DNA synthesis-dependent proteins such 
as TS. TS levels are also controlled at the level 
of translation (3). The translation of TS-mRNA 
appears to be controlled by its end product, the 
TS protein, in an autoregulatory manner. TS 
protein cannot only regulate its own translation 
but also that of other proteins, such as p53 (4). In 
addition, wild-type p53 protein can also inhibit 
TS promotor activity (5). 
5-Fluorouraci l  (5-FU) i s  an  impor tant 
antineoplastic agent that has proven to be 
effective in the treatment of colorectal cancer, 
stomach cancer and breast cancer. (6) The active 
metabolite of 5-FU, 5-fluoro-2’-deoxyuridine-
5’-monophosphate (FdUMP) inhibits TS, which 
is increased in tumors compared to normal cells. 
TS inhibition by FdUMP is mediated by the 
formation of a covalent ternary complex between 
FdUMP, TS and 5-10-CH2-THF (1). This leads 
directly to depletion of dTMP and indirectly 
to an accumulation of dUMP. As a result the 
5-FU metabolite 5-fluoro-2’-deoxyuridine-5’-
triphosphate (FdUTP) is incorporated into DNA 
due to lack of natural substrate dTTP. In addition, 
5-fluoro-uridine-5’-triphosphate (5-FUTP), 
another metabolite of 5-FU can be incorporated 
into RNA. (1)
One of the main obstacles for the clinical use of 
5-FU is the acquisition of resistance to the drug 
by cancer cells. In vitro studies have demonstrated 
that a major mechanisms of resistance is due to 
an increased activity of TS. This activity can have 
several reasons, such as gene amplification and 
altered autoregulation (1, 3, 7, 8). Autoregulation 
Fig. 1: Proposed mechanism of action combining checkpoint abrogators with DNA damaging agents such as the 
pyrimidine analogue 5-FU (modified from 10); 
A: DNA incorporation of drug metabolites or inhibition of TS induces an S phase arrest. Activation of Chk-1 
deactivates the cdk1-cylin B complex inhibiting G2/M transition. 
B: When DNA damage is combined with checkpoint abrogators such as UCN-01, cells are also arrested in the G2-M 
phase since UCN-01 is able to inhibit Chk1, 5-FU damaged cells go into mitosis, but the accumulated damage 
leads to mitotic cell death. UCN-01 and staurosporin also inhibit Cdk2/cyclinE. This leads to a lower extent of RB 
hyperphosphorylation, stabilizing the complex Rb-E2F, less free E2F and less free TS, which can be inhibited more 
efficiently by 5-FU. 
A
B
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of TS-mRNA translation controls the normal 
level of TS protein, but binding by FdUMP 
disrupts this process leading to increased TS 
protein. TS protein can also increase due to 
aberrant regulation by cell cycle genes, such as 
Rb and E2F (9). The TS gene has an E2F binding 
site in its promoting region (2), leading to more 
synthesis of TS protein (Fig. 1). These results 
suggested that E2F-1 plays an important role in 
the acquisition of 5-FU-resistance by cancer cells 
(9) and that cancer therapy targeting transcription 
factor E2F might be effective (2). 
Cell  cycle perturbations are commonly 
observed in human malignancies. Protein 
kinases participate in growth factors and 
oncogene product-dependent signal transduction 
pathways and have emerged as key regulators 
of cell proliferation (10, 11). Staurosporine 
(STS) and staurosporine analogs such as 
7-hydroxystaurosporine (UCN-01) are protein 
kinase C (PKC) inhibitors but can also inhibit 
other cell cycle regulating enzymes. UCN-01 has 
been tested both as an enhancer of cytotoxicity 
of other drugs and as a single cytotoxic agent 
(10). The potentiation of cytotoxicity by UCN-
01 is assumed to be due to its ability to abrogate 
the S- or the G2/M-phase checkpoints (11, 12). 
The by-pass of these cellular checkpoints in the 
presence of DNA damage would lead the cell 
to death. At the molecular level, it was found 
that UCN-01 also inhibits chk1 kinase, which 
leads to activation of cdc25C phosphatase and 
inhibition of Wee1 kinase, resulting in increased 
Cdc2/cyclin B1 activity (11). UCN-01 induces 
apoptosis in various human tumor cell lines. 
The precise mechanism of UCN-01 antitumor 
activity is still not completely understood (10, 
11, 12, 13). UCN-01 does not interact with 
DNA in both cell-free and cellular systems nor 
causes single-strand or double strand breaks in 
vitro (10). It was however clearly shown, that 
the induction of apoptosis by UCN-01 does 
not correlate with its ability to inhibit PKC 
activity (10). UCN-01 can inhibit activation and 
phosphorylation of protein kinase B (Akt), in 
vitro and in vivo (10). Inhibition of Akt activity 
correlated with UCN-01 induced apoptosis, 
thus suggesting that UCN-01 may exhibit 
its cytotoxicity in part by turning off the Akt 
survival pathway. In vitro and in vivo, UCN-01 
selectively blocks cell cycle progression from 
G1- to S-phase and preferentially induces G1-
phase accumulation of the target cells. UCN-01 
induced G1-phase accumulation is associated 
with inhibition of cdk2 kinase. Inhibition of 
cdk2 kinase takes place by the induction of cdk 
inhibitors such as p21cip1 and p27kip1 or, as it was 
hypothesized, by interaction of UCN-01 with 
the ATP binding site of cdk2 (12) (Fig. 1). It was 
postulated that G1-phase arrest resulting from 
inhibition of cdk2 activity might be associated 
with apoptosis induced by UCN-01.
In this study we investigated the potential 
of UCN-01 and staurosporine to increase the 
cytotoxicity of the DNA damaging agent 5-FU. 
For this purpose we used the colon cancer cells 
Lovo B2 (wild type p53) and Lovo 175x2 (mutant 
p53). Mechanistic studies focused on interaction 
between TS and cell cycle proteins, leading to 
cell cycle disturbance and cell death. 
Materials and Methods
Materials
5-FU, UCN-01 and staurosporine were 
purchased from Sigma Chemical Co (St Louis, 
MO, UK). [5-3H] dUMP (TRK-287; specific 
activity 19 Ci/mmol) was purchased from 
Amersham International (Buckinghamshire, 
UK). The primary antibody mouse antihuman 
TS (clone TS 106)  was from Labvis ion, 
Neomarker, the primary monoclonal E2F-1, 
recognizing the first 368 amino acids was from 
SantaCruz, the polyclonal rabbit antihuman 
phospho-Chk1 (Ser 345) antibody was from 
Cell Signaling Technology (USA), while the 
secondary antibodies-goat anti-rabbit IgG HRP 
was from Santa Cruz Biotechnology (USA) and 
the polyclonal goat anti-mouse-from Dako A/
S (Denmark). Unless otherwise specified, all 
other chemicals were of analytical grade and 
commercially available.
Cell culture
The source,  characterist ics and culture 
conditions of the colon cancer cell lines, LovoB2 
(wild type p53) and Lovo175x2 (mutant p53) 
were described earlier (5). Briefly cells were 
cultured at 370C in 5%CO2 in DMEM medium 
supplemented with 10% fetal calf serum and 
20 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]-
ethanesulfonic acid (HEPES). 
A n t i - p r o l i f e r a t i v e  e f f e c t s  o f  5 - F U , 
staurosporine, UCN-01 and their combinations 
on LovoB2 and Lovo 175x2 colon cancer cells 
were evaluated using the sulforhodamine B 
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(SRB) assay, as described earlier (14). Briefly 
cells were plated in 96-wells plates; after 24 hr 
one plate (d 0) was processed as control, to the 
other plates drugs were added and processed 
after 72 hr. For the combinations a fixed ratio 
was used of 5-FU and the PKC inhibitors (100:1) 
with concentrations ranges of 0.1-50 µM for 
5-FU and 0.001-0.5 µM for staurosporine/UCN-
01. For sequential combinations, UCN-01 or 
staurosporin were first added, followed after 24 
hr by 5FU. In order to evaluate the combinations 
the multiple drug effect analysis was used as 
described earlier (15); the interaction between 
drugs was expressed as the Combination Index 
(CI). Values obtained at fraction affected (FA) 
of 0.5, 0.75 and 0.9 were averaged and used 
to calculated the means of at least 3 separate 
experiments. A mean CI < 0.9 was considered as 
synergistic, > 1.1 as antagonistic and 0.9 – 1.1 as 
additive (15).
Cell cycle changes and induction of apoptosis
After 24 hr and 48 hr drug exposure of cells 
using IC80 concentrations (final concentrations: 
5  μM 5-FU,  0 .5  μM UCN-01 ,  0 .05  μM 
staurosporine), adherent and floating cells 
were harvested and used for cell cycle analysis 
and cell death (sub-G1) using Fluorescence-
activated cells sorter (FACS) flow cytometer 
(Becton Dickinson) based on double stranded 
DNA binding properties of propidium Iodide as 
described earlier (16). The programme Cellquest 
was used for analysis. 
Western Blot analysis
In order to evaluate expression of TS and the 
cell cycle proteins E2F and Phospho-Chk1, cells 
were harvested and prepared for western blot 
analysis as described earlier (16). The target 
was visualized by means of ECL(+) detection as 
described.
TS-catalytic assay
In order to evaluate the effect of the drugs, cells 
were exposed to 5 µM 5FU, 0.5 µM UCN-01 or 
0.05 µM staurosporin alone or in combination. 
Cells were harvested after 24, 48 and 72 hr, and 
the TS catalytic activity was determined at 1 µM 
dUMP as described earlier (17). 
Results
Drug sensitivity and combinations 
Table 1: Sensitivity of Lovo variants to 5FU, stauro-
sporine and UCN-01.
 IC50 (µM) Lovo B2
(wild –type)
Lovo 175x2
(mut-p53)
Staurosporine  0.003 + 0.0006 0.005 + 0.0009      
UCN-01 0.02   + 0.002          0.091 + 0.014
5-FU 1.86   + 0.38 3.98   + 0.79
Sensitivity to the drugs was determined using the SRB 
assay after 72 hr to the drugs. Values are means + SE of 
at least 3 separate experiments
Table 2: Multiple drug effect analysis for combinations of  UCN-01 with 5FU and staurosporin with 5-FU in Lovo 
variants 
Simultaneous Sequential
Lovo Lovo 175x2 Lovo Lovo175x2
UCN-01 + 5FU 0.42 ± 0.03 0.21 ± 0.01 0.76 ± 0.27 0.97 ± 0.24
Staurosporin + 5FU 0.79 ± 0.12 0.87 ± 0.14 0.53 ± 0.07 1.98 ± 0.30
Values are means + SD of at least 3 separate experiments. Cells were exposed to the drugs simulataneously for 72 hr, 
or sequentially (24 hr UCN-01 or staurosporin, followed by the combination of UCN-01 + 5FU or staurosporin + 5FU 
for 48 hr.
Fig. 2: Example of the synergistic interaction between 
5FU and UCN-01 in Lovo175x2 cells. Cells were 
exposed simultaneously to 5FU and UCN-01 for 72 hr, 
after which the SRB assay was performed to evaluate 
growth inhibition. Synergism was determined using the 
multiple effect analysis. The broken indicates the cut-off 
between antagonism (CI>1.1) and synergism (CI<0.9), 
showing a clear synergism at FA>0.3 and very synergistic 
at FA>0.7.
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The sensitivity to 5-FU, staurosporine and 
UCN-01 was determined after 72 hr exposure 
to the drugs (Table 1). The wild-type cells were 
more sensitive to 5FU and staurosporin, but 
not to UCN-01. The effect of the combinations 
was studied using simultaneous and sequential 
c o m b i n a t i o n s .  A l l  c o m b i n a t i o n s  w e r e 
synergistic when cells were exposed to the drugs 
simultaneously; the staurosporin combination 
was moderately synergistic (CI values about 0.8-
0.9), but that with UCN-01 was highly synergistic 
with CI values varying from 0.2-0.4 (Table 2, Fig 
2). Sequential combinations were less synergistic, 
being additive or even antagonistic in the mutp53 
Lovo175x2 cells. 
Cell cycle changes and induction of apoptosis
Since staurosporin and UCN-01 are cell cycle 
directed drugs, we determined their effect, alone 
and in combinations, on cell cycle distribution 
(Fig. 3). In both untreated Lovo variants 45-60% 
of the cells were in G1 phase, 10-15%-in S-phase 
and 30-40% -in G2/M phase. UCN-01 caused 
an accumulation of cells in the G2/M phase 
(60% after 24 hr, decreasing to 40% after 48 hr). 
Staurosporin, however, increased accumulation 
of cells to 50-60% in the G1 phase, which was 
more pronounced in the Lovo wild type cells. 
5FU induced a clear accumulation of cells in the 
S-phase (30% after 24 hr and 40% after 48 hr). In 
the simultaneous combinations the 5FU induced 
S-phase accumulation after 24 hr seemed to be 
predominant, which was even more pronounced 
in the mut p53 cells, both for the staurosporin and 
UCN-01 combinations. However, after 48 hr this 
effect was less. For the sequential combinations 
the effect of the first drug seemed to be most 
important for the cell cycle distribution, i.e. 
Fig. 3: Effect of 0.5 µM UCN-01 (UCN), 0.05 µM staurosporine (STS) and 5 µM 5FU, alone and in combination 
on the cell cycle distribution of Lovo and Lovo 175x2 cells. Cells were exposed for 24 or 48 hr. At the 48 hr time-
point sequential combinations were studied as well, in which cells were exposed to 5FU for 24 hr followed by the 
combination for 24 hr (5FU>UCN and 5FU>STS) or 24 hr hr to UCN-01 or staurosporine followed by the combination 
for 24 hr (UCN>5FU and STS>5FU). Values are means of 3 separate experiment; SD were less then 5%.
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with 5FU first, the cell cycle distribution after 
48 hr resembled that of 5FU alone (S phase 
accumulation), but with staurosporin first more 
cells accumulated in the G0-G1 phase, while 
with UCN-01 first more cells accumulated in the 
G2-M phase.
Both staurosporin and UCN-01 already induced 
a clear cell kill after 24 hr, increasing after 48 hr 
(Fig. 4). Especially for UCN-01 cell kill was more 
pronounced in the mut p53 cells. Cell kill induced 
by 5FU was moderate, even after 48 hr. In the 
combinations with staurosporin the simultaneous 
combination was less effective in wt p53 cells. In 
the sequential combinations, 5FU first was most 
effective. For UCN-01 combinations a higher 
cell kill (up to 35%) was observed in the mutp53 
cells compared to less then 15% in the wt cells. 
The extent of cell kill was independent of the 
sequence. 
Expression of TS and upstream proteins-E2F-1 
and pChk1
In order to get more insight in the mechanism 
of the drug interactions we determined expression 
of TS and the cell cycle proteins E2F and pChK1. 
Treatment of LovoB2 cells for 24 hr with 5FU 
reduced the expression of free TS by trapping TS 
in the ternary complex detected at 38 kD (Fig. 
5A). The total amount of TS increased as well. 
Staurosporin alone did not affect TS expression at 
24 hr, but UCN-01 alone decreased the expression 
of TS at 24 hr. At 48 hr TS was undetectable 
after treatment with UCN-01 or staurosporin. 
Both staurosporin and UCN-01 decreased TS 
expression. In the combination initial trapping 
of TS in the ternary complex was not affected by 
staurosporin or UCN-01 at 24 or 48 hr (Fig. 5A).  
In order to explain the downregulation of TS, 
we also determined the expression of E2F and 
pChK1, which play a crucial role on G1-S and 
G2-M transition, respectively. Both staurosporin 
and UCN-01 downregulated the expression 
of E2F after 24 hr (Fig. 5B), but the effect of 
UCN-01 was more pronounced. Also in the 
combination with 5FU, E2F was downregulated, 
indicating the formation of the ternary complex 
was independent of E2F. When 5FU preceded 
staurosporin or UCN-01 the downregulation of 
E2F after 48 hr was less then when 5FU was 
given after staurosporin or UCN-01. 
Fig. 4: Effect of 0.5 µM UCN-01 (UCN), 0.05 µM staurosporine (STS) and 5 µM 5FU, alone and in combination on 
cell death as measured by sub-G1 accumulation in Lovo and Lovo 175x2 cells. Cells were exposed for 24 or 48 hr. 
At the 48 hr time-point sequential combinations were studied as well, in which cells were exposed to 5FU for 24 hr 
followed by the combination for 24 hr (5FU>UCN and 5FU>STS) or 24 hr hr to UCN-01 or staurosporine followed by 
the combination for 24 hr (UCN>5FU and STS>5FU). Values are means of 3 separate experiment; SD were less then 
5%.
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The expression of pChk1 expression was 
undetectable in control samples of LovoB2 and 
Lovo175x2 cells. Staurosporin and UCN-01 did 
not increase the expression of pChK1, but 24 hr 
5FU treatment did, both alone and in combination 
with staurosporin or UCN-01. However, after 48 
hr the expression was undetectable again. 
Effect on TS levels
Since TS inhibition is crucial in the efficacy 
of 5FU we determined the catalytic TS activity 
in LovoB2 and Lovo175x2 cells (Fig. 6). TS 
activity in LovoB2 cells was clearly decreased 
in staurosporin and UCN-01 treated cells, while 
at the used 5FU concentration TS inhibition 
was moderate, as found earlier (17). This 
Fig. 5: Effect of 0.5 µM UCN-01 (UCN), 0.05 µM staurosporine (STS) and 5 µM 5FU, alone and in combination on 
expression of TS and the cell cycle proteins E2F and pChk1. 
A: the effect on TS (native protein 36 kD; ternary complex 38 kD) after 24 and 48 hr exposure in Lovo B2 cells. 
B: the effect on E2F and pChk1 expression in Lovo B2 cells. 
Cells were exposed for 24 or 48 hr. At the 48 hr time point sequential combinations were studied as well, in which cells 
were exposed to 5FU for 24 hr followed by the combination for 24 hr (5FU>UCN and 5FU>STS) or 24 hr to UCN-
01 or staurosporine followed by the combination for 24 hr (UCN>5FU and STS>5FU). Equal loading of the blots was 
controlled by β-actin. Blots are representative of 3 separate experiments.
A B
Fig 6. Effect of 5 µM 5FU, 0.5 µM UCN-01 or 0.05 µM staurosporine (STS) on the catalytic activity of TS in Lovo B2 
and Lovo175x2 cells. Cells were exposed for 24 or 48 hr. 
A: exposure of Lovo B2 and Lovo175x2 cells for 24 hr, alone and in combination.
B: Exposure of Lovo B2 cells for 48 hr, at which sequential combinations were studied as well; cells were exposed 
to 5FU for 24 hr followed by the combination for 24 hr (5FU>UCN and 5FU>STS) or 24 hr hr to UCN-01 or 
staurosporine followed by the combination for 24 hr (UCN>5FU and STS>5FU). 
Values are means of 2 separate experiment; SD were less then 15%.
A B
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concentration was used, because at a moderate 
inhibition, a modulating effect can be studied. 
In the combination of 5FU with staurosporin an 
intermediate effect was observed, which was less 
in staurosporin treated cells. In Lovo175x2 cells 
the results were comparable. 
Discussion
This study shows that modulation of 5FU by 
cell cycle abrogation can enhance the cytotoxicity 
of the combination, not only in wt p53, but the 
effects of UCN-01 were even more pronounced in 
mut p53 cells. These effects were clearly related 
to cell cycle abrogation of the compounds.
Both 5FU and the PKC inhibitors staurosporin 
and UCN-01 can exert cytotoxic effects. 5FU 
is a potent inhibitor of TS by formation of a 
ternary complex (1). The efficacy of 5FU can be 
enhanced by an increase of TS inhibition, which 
can be achieved by either decreasing the levels 
of TS or stabilizing the ternary complex. TS is 
a cell cycle dependent enzyme, and regulated 
by the transcription factor E2F (2). Hence 
deregulation of the cell cycle by a decrease 
in E2F can decrease TS expression. Indeed in 
wtp53 cells UCN-01 decreased E2F as well as 
TS expression, preventing cells to accumulate 
in the S-phase; however, in mut p53 cells, 5FU 
induced accumulation of cells in the S-phase is 
partly prevented when UCN-01 preceded 5FU. 
Under these conditions more cell kill is observed, 
possibly because cells can not continue to cycle 
since UCN-01 also inhibits the G2-M checkpoint. 
Phosphorylation of Chk1 was observed in cells 
exposed to 5-FU possibly as a response to the 
DNA damage caused by 5-FU. Since UCN-01 
inhibits Chk1 kinase (11), this leads to activation 
of cdc25 phosphatase preventing phosphorylation 
of cdk1/cyclin B1. 5FU damaged cells go into 
mitosis and die. In the case of staurosporin, 
mitosis is not inhibited since cells accumulate in 
the G0-G1. 5-FU damaged cells accumulate in 
the S-phase, but will be prevented to cycle further 
after staurosporin treatment.
Further evidence for a dual cytotoxic effect, 
mediated by 5FU induced DNA damage and cell 
cycle abrogation, is shown by the effect on TS 
activity and expression. A decrease in TS levels 
was seen both by western blotting and activity 
assays. For 5FU this was a clear inhibition as 
seen by the ternary complex formation, but for 
UCN-01 this was clearly a decrease in E2F 
leading to a decrease in TS. For staurosporin 
this effect was delayed and only seen after 48 hr. 
Hence we saw a dual effect on TS, one which 
can be explained partly by the autoregulation 
of TS mRNA translation as proposed by Liu 
et al (3), or stabilization of TS as proposed by 
Kitchens et al (18). The effect of UCN-01 in 
relation to TS is an agreement with other studies 
showing that transfection of E2F decoy ODN 
(oligodeoxynucleotides) resulted in decreased TS 
mRNA expression (9).
In conclusion, cytotoxicity of 5FU can be 
enhanced by the PKC inhibitors staurosporin and 
UCN-01. However, cell kill by the combination 
with staurosporin is also mediated by prevention 
of cell cycling, leading to enhanced DNA 
damage. In contrast, cell kill mediated by UCN-
01 by be related to a mitotic arrest.
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